文献速递骨质疏松与钙磷/甲状旁腺

维生素D补充预防佩吉特病双膦酸盐输注后急性期反应

Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本研究在330例佩吉特骨病患者中观察含氮双膦酸盐输注后急性期反应(APR)的危险因素,并在66例活动未治疗患者中开展干预研究。结果显示维生素D缺乏越重APR风险越高,25OHD低于10 ng/mL者APR达80.0%;补充维生素D可显著降低APR风险(RR=0.31)。

要点

  • 25OHD低于10 ng/mL者APR发生率高达80.0%,风险随维生素D缺乏加重而升高。
  • 既往发生过APR或携带SQSTM1突变者APR风险分别升高至2.8倍和2.3倍。

核心结论

  • 佩吉特骨病患者在含氮双膦酸盐输注前应达到充足25OHD水平,以降低急性期反应或低钙血症风险。

研究设计与样本

  • 对330例佩吉特骨病患者在含氮双膦酸盐输注时进行观察性分析。

主要发现

  • 回顾性分析中,初治和既往治疗患者APR发生率分别为47.6%和18.3%。
  • APR患病率随维生素D缺乏严重程度递增,25OHD低于10 ng/mL者达80.0%(RR=3.7;95%CI 2.8-4.7;P<.0001)。
  • 既往发生APR者APR风险升高(RR=2.8;95%CI 1.5-5.2;P<.001),SQSTM1突变携带者风险亦升高(RR=2.3;95%CI 1.3-4.2;P=.005)。
  • 干预研究中维生素D补充使APR风险相对观察队列降低(RR=0.31;95%CI 0.14-0.67;P<.005),低钙血症呈现类似趋势。

关键数值与推荐

  • 25OHD低于10 ng/mL时APR发生率为80.0%(RR=3.7;95%CI 2.8-4.7;P<.0001)。
  • 既往APR史者APR的RR=2.8(95%CI 1.5-5.2;P<.001)。
  • SQSTM1突变携带者APR的RR=2.3(95%CI 1.3-4.2;P=.005)。
  • 维生素D补充预防APR的RR=0.31(95%CI 0.14-0.67;P<.005)。
  • 推荐含氮双膦酸盐输注前达到充足25OHD水平以减少APR或低钙血症风险。

临床怎么用

  • 佩吉特骨病患者启动含氮双膦酸盐静脉治疗前应检测并纠正25OHD至充足水平。
  • 对既往有APR史或携带SQSTM1突变者应尤其重视输注前维生素D状态评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Intravenous aminobisphosphonates (N-BPs) can induce an acute phase reaction (APR) in up to 40% to 70% of first infusions, causing discomfort and often requiring intervention with analgesics or antipyretics. OBJECTIVE: Our aim was to explore the risk factors of APR in a large sample of patients with Paget's disease of bone (PDB) and to assess the possible preventive effects of vitamin D administration. METHODS: An observational analysis was performed in 330 patients with PDB at the time of N-BP infusion. Then, an interventional study was performed in 66 patients with active, untreated PDB to evaluate if vitamin D administration (oral cholecalciferol 50 000 IU/weekly for 8 weeks before infusion) may prevent APR. RESULTS: In a retrospective study, APR occurred in 47.6% and 18.3% of naive or previously treated patients, respectively. Its prevalence progressively increased in relation to the severity of vitamin D deficiency, reaching 80.0% in patients with 25-hydroxyvitamin D (25OHD) levels below 10 ng/mL (relative risk (RR) = 3.7; 95% confidence interval (CI) 2.8-4.7, P < .0001), even in cases previously treated with N-BPs. Moreover, APR occurred more frequently in patients who experienced a previous APR (RR = 2.8; 95% CI 1.5-5.2; P < .001) or in carriers of SQSTM1 mutation (RR = 2.3; 95% CI 1.3-4.2; P = .005). In the interventional study, vitamin D supplementation prevented APR in most cases, equivalent to a RR of 0.31 (95% CI 0.14-0.67; P < .005) with respect to prevalence rates of the observational cohort. A similar trend was observed concerning the occurrence of hypocalcemia. CONCLUSIONS: The achievement of adequate 25OHD levels is recommended before N-BP infusion in order to minimize the risk of APR or hypocalcemia in PDB.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Merlotti D, Rendina D, Muscariello R, et al. Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease. J Clin Endocrinol Metab. 2020. PMID: 31634910. doi:10.1210/clinem/dgz138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。